Jonathan Root

The Doctor Who Never Left the Room

Most venture capitalists arrive at Sand Hill Road via banking, consulting, or a successful exit. Jonathan Root arrived via the Neurology-Neurosurgery Intensive Care Unit at New York Hospital-Cornell Medical Center, where he was director, and before that, a practicing board-certified neurologist and Assistant Professor of Neurology. Nine years in clinical medicine is not a footnote on his bio. It is the engine of his investing thesis.

Root joined U.S. Venture Partners in 1995 as an Ewing Marion Kauffman Fellow - part of the charter class of a program specifically designed to bring talent from medicine, science, and other fields into venture capital. Two years later, he became a General Partner. He has been one ever since.

That single sentence explains a lot. Root doesn't evaluate medical startups from a spreadsheet. He evaluates them from the vantage point of a doctor who has prescribed treatments, used devices, and watched what happens when brilliant technology meets the friction of a hospital environment. The test is not elegance. The test is adoption. Will a surgeon actually use this? Will a patient comply? Will an insurer pay for it?

His focus at USVP is early-stage - pre-seed, seed, and Series A - primarily medical devices, biotech, and healthcare IT, with a sweet spot investment of around $6 million. That early timing is deliberate. Root wants to be in when the science is uncertain, before the valuation has priced in the promise. He has the clinical knowledge to assess whether the underlying biology or engineering is credible - and the investor experience to know which teams can execute.

The exits validate the judgment. Inari Medical, which developed a minimally invasive treatment for venous thromboembolism, was acquired by Stryker Corporation in February 2025. MicroVention, Lutonix, Cryovascular Systems, Proteolix, Sequent Medical - the list of USVP portfolio companies acquired by large medical device and pharma companies is long. Each one represents a bet Root made early, often before the category had a name.

Root's current portfolio shows the same pattern: companies working in spaces that are hard, technically complex, and not yet crowded. Carlsmed builds AI-guided implant selection for spine surgery. Cleave Biosciences and eFFECTOR Therapeutics are going after translation initiation in cancer - a mechanism most oncology investors haven't touched. Route 92 Medical is redesigning neurovascular access systems used in stroke intervention. Okami Medical is developing devices for left atrial appendage management in atrial fibrillation. These are not consumer apps with hockey-stick user growth curves. They are bets on science.

Outside of writing checks, Root serves on the investment advisory committee at Mission Bay Capital, the UCSF-affiliated early-stage health fund. He sat on the board of the National Venture Capital Association and chaired the NVCA's Medical Industry Group - the trade body's dedicated arm for healthcare investing. He is also a member of the Dartmouth Innovations Accelerator for Cancer External Review Panel, keeping one foot in academic medicine even 30 years after leaving clinical practice.

U.S. Venture Partners itself is one of the older venture firms in Silicon Valley, founded in 1981. USVP has invested across technology and life sciences, with a particular emphasis on early-stage Bay Area companies. The December 2022 raise of a $400 million fund - USVP's latest - was completed against a backdrop of significant market volatility, a signal of continued LP confidence in the firm's thesis and team. Root is the medical cornerstone of that team.

The Omada Health board seat illustrates the breadth of Root's portfolio. Omada is a digital therapeutics company that uses behavioral science and remote monitoring to manage chronic conditions - a company built at the intersection of software and clinical protocol. Root has held that seat since 2013, a relationship that predates the mainstream explosion of "digital health" as a category. He was there when the category was still being invented.